What is the total amount CVS Health raised through this filing?

CVS Health raised a total of $5.5 billion through the issuance and sale of its Notes and ECAPSSM. The net proceeds after expenses were approximately $5.4 billion.

What will the proceeds from this offering be used for?

A significant portion of the net proceeds will be used to reduce outstanding debt under the company's Bridge Credit Facility. The exact allocation beyond this is not detailed in this specific filing, but raising substantial capital suggests it could be for general corporate purposes, strategic initiatives, or debt management.

What is the significance of the Replacement Capital Covenant (RCC)?

The Replacement Capital Covenant is a restrictive agreement related to the ECAPSSM. It prevents CVS Health and its subsidiaries from repaying, redeeming, or purchasing these securities before June 1, 2047, unless they issue a specified amount of certain replacement capital securities under defined terms. This covenant is designed to provide long-term stability for the ECAPSSM structure and to protect holders from early redemption under certain circumstances.

What types of debt securities were issued?

CVS Health issued $4.5 billion in Senior Notes, consisting of $1.75 billion in Floating Rate Senior Notes due 2010, $1.75 billion in 5.750% Senior Notes due 2017, and $1.0 billion in 6.250% Senior Notes due 2027. Additionally, $1.0 billion of 6.302% Enhanced Capital Advantaged Preferred Securities (ECAPSSM) due 2062 were issued.

CVS 8-K: Material Agreements

Summary

CVS Health Corporation (then CVS Caremark Corporation) filed an 8-K on May 25, 2007, to report the entry into material definitive agreements related to a significant debt and preferred securities offering. The company entered into underwriting agreements to issue and sell $4.5 billion of Notes and $1.0 billion of Enhanced Capital Advantaged Preferred Securities (ECAPSSM). This offering aimed to raise substantial capital, with net proceeds of approximately $5.4 billion after deducting underwriter discounts and expenses. The primary purpose of this filing is to inform investors about the terms and execution of these agreements. The issuance of these securities, including Floating Rate Senior Notes, Fixed Rate Senior Notes across different maturities, and ECAPSSM, was registered under a Form S-3 filing on May 21, 2007. A portion of the proceeds is intended to reduce outstanding debt under a Bridge Credit Facility. Additionally, a Replacement Capital Covenant was put in place for the ECAPSSM, restricting repayment or redemption before June 1, 2047, unless specific replacement capital is issued.

Key Highlights

1CVS Health Corporation (as CVS Caremark Corporation) announced the issuance and sale of $4.5 billion in Senior Notes and $1.0 billion in Enhanced Capital Advantaged Preferred Securities (ECAPSSM) through separate underwriting agreements.
2The total aggregate principal amount for the securities offering is $5.5 billion.
3Net proceeds from the offering are estimated to be approximately $5.4 billion after accounting for underwriter discounts and estimated offering expenses.
4The offerings were made pursuant to a Registration Statement on Form S-3 filed on May 21, 2007.
5The Senior Notes include maturities of 2010 (Floating Rate), 2017 (5.750%), and 2027 (6.250%).
6A Replacement Capital Covenant (RCC) was executed, restricting the repayment or redemption of ECAPSSM before June 1, 2047, unless certain conditions regarding replacement capital are met.
7A portion of the net proceeds from the offering will be used to reduce outstanding debt under the Bridge Credit Facility.

CVS HEALTH Corp 8-K Report, Material Agreement (May 25, 2007)

Summary

Key Highlights

Frequently Asked Questions